JH-RE-06

SKU: orb1308178

Description

JH-RE-06 is a small molecule inhibitor of the REV1-REV7 interaction, effectively blocking mutagenic POLζ recruitment during translesion synthesis (IC50=0.78 μM). It serves as a chemical probe for studying DNA damage tolerance and has shown potential to enhance chemotherapy efficacy in preclinical cancer models.

Research Area

Cell Biology, Molecular Biology

Key Properties

• CAS Number: 1361227-90-8
• MW: 468.72
• Purity: 99.29% (May vary between batches)
• Formula: C₂₀H₁₆Cl₃N₃O₄
• SMILES: CC(C)CC(=O)c1c(Nc2ccc(Cl)cc2Cl)[nH]c2c(Cl)ccc([N+]([O-])=O)c2c1=O
• Target: DNA/RNA Synthesis
• Solubility: DMSO:10.91 mg/mL (23.28 mM)

Bioactivity

• Target IC50:
  Rev1-Rev7:0.42 μM (Kd)|Rev1-Rev7:0.78 μM (IC50)
• In Vivo:
  In mice, co-administration of JH-RE-06 with cisplatin inhibits the growth of xenograft human melanomas. JH-RE-06 suppresses mutagenic TLS and increases cisplatin-induced toxicity in cultured human and mouse cell lines .
  Read more...
• In Vitro:
  JH-RE-06 unexpectedly causes dimerization of the REV1 CTD at its REV7-binding surface. It also blocks the REV1-REV7 interaction.

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

RNA Synthesis, RNASynthesis, REV1-REV7, Inhibitor, inhibit, JH RE 06, JH-RE-06, JHRE06, DNASynthesis, DNA Synthesis, DNA/RNA Synthesis

Compound Identifiers

PubChem CID

70691604